(April29, 2015 – Hong Kong) On April 29, 2015, Shanghai Fosun Pharmaceutical (Group)Co., Ltd. (“Fosun Pharma” or the “Company”; stock code: 600196-SH，02196-HK), the leading pharmaceutical and healthcare enterprise in China,announced its first quarterly operating results ended March 31, 2015.

In the firstquarter of 2015, the Company achieved an operating revenue of RMB2,800 million,representing an increase of 5.36% as compared with the correspondent period oflast year; net profit attributable to equity holders of the Company amounted toRMB536 million, representing an increase of 29.02% as compared with thecorrespondent period of last year.

TheCompany actively optimizes business and products structure, continues toenhance its core competiveness. In respect of pharmaceutical manufacturing aswell as research and development, the core formulation products enjoyed goodsales achievements in the first quarter. In the sector of healthcare services,the Company accelerates the business layout of United Family Healthcare indeveloped cities. In the meantime, the Company strives to rapidly expand theoperating scale of healthcare services. Previously announced projects inTaizhou cooperated with public hospitals are proceeding smoothly as scheduled.

TheManagement of the Company indicates that the Company will continue to carryforward the strategic approach of “Organic Growth, Coupled with M&A andIntegration” during the period of booming business development. Centered on thecore pharmaceutical and healthcare businesses, the Company will ceaselesslyimprove its capability of innovation and level of management, and expand theindustry of healthcare services.